| Author and year of publication |
Study Design |
Title |
Location |
Number of Patient |
Course Duration |
| Julio Rosenstock 2021 [19] |
Randomized Controlled Trials. Phase 3 trial. Multi-Center. |
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. |
India, Japan, Mexico, and United States. |
Tirzepatide 5mg: 121 Tirzepatide 10mg: 121 Tirzepatide 15mg: 121 Vs Placebo: 115 |
40 weeks |
| Dominik Dahl 2022 [23] |
Randomized Controlled Trials, Double-blind. Phase 3 trial. |
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. |
Germany, Poland, Japan, and United States |
Tirzepatide 5mg: 116 Tirzepatide 10mg: 119 Tirzepatide 15mg: 120 Vs Placebo: 120 |
40 weeks |
| Juan Pablo Frias 2021 [24] |
Randomized Controlled Trials. Phase 3 trial. |
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. |
128 sites in Australia, Argentina, and United States. |
Tirzepatide 5mg: 470 Tirzepatide 10mg: 469 Tirzepatide 15mg: 470 Vs Semaglutide 1mg: 469 |
40 weeks |
| Bernhard Ludvik 2021 [25] |
Randomized Controlled Trials. Phase 3 trial. Multi-Center. |
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. |
Argentina, Austria, Greece, Hungary, and Poland. |
Tirzepatide 5mg: 358 Tirzepatide 10mg: 360 Tirzepatide 15mg: 359 Vs Insulin Degludec: 360 |
52 weeks |
| Juan Pablo Frias 2020 [26] |
Randomized Controlled Trials, Double-blind. Phase 2 trial. |
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. |
United State |
Tirzepatide 15mg: 28 Vs Placebo: 26 |
12 weeks |
| Juan Pablo Frias 2018 [27] |
Randomized Controlled Trials. Phase 2 trial. |
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial |
47 sites in Poland, Puerto Rico, Slovakia, and United States |
Tirzepatide 5mg: 55 Tirzepatide 10mg: 51 Tirzepatide 15mg: 53 Vs Dulaglutide 1.5mg: 54 Placebo: 51 |
26 weeks |
